Concurrent endometrial carcinoma in patients with a curettage diagnosis of endometrial hyperplasia

Journal of the Formosan Medical Association

Volumn 108, Issue 6, 2009, Pages 502-507

  Chen, Yu Li ^a   Cheng, Wen Fang ^a   Lin, Ming Chieh ^a   Huang, Chia Yen ^a   Hsieh, Chang Yao ^a   Chen, Chi An ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Endometrial carcinoma; Endometrial hyperplasia; Hysterectomy

Indexed keywords

ADULT; ARTICLE; BODY MASS; COMORBIDITY; CURETTAGE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 67651242217     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60098-X     Document Type: Article

References (28)

1. Silverberg SG. Tumors of the uterine corpus and gestational trophoblastic disease. In: Silverberg SG, Kurman RJ, eds. Atlas of Tumor Pathology, 3rd Series, Fascicle 3. Washington, DC: Armed Forces Institute of Pathology, 1992:13-14
2. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76:287-290
3. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004;59:368-378
4. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;160:126-131
5. Gusberg SB, Kaplan AL. Precursor of corpus cancer. IV. Adenomatous hyperplasia as stage 0 carcinoma of the endometrium. Am J Obstet Gynaecol 1963;87:662-678
6. Parazzini F, La Vecchia C, Bocciolone L, et al. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
7. Announcements. FIGO Stages-1988 Revision. Gynecol Oncol 1989;35:125-127
8. Soslow RA. Problems with the current diagnostic approach to complex atypical endometrial hyperplasia. Cancer 2006;106:729-731
9. King A, Seraj IM, Wagner RJ. Stromal invasion in endometrial adenocarcinoma. Am J Obstet Gynaecol 1984;149:10-14 (Pubitemid 14148863)
10. Merisio C, Berretta R, De Ioris A, et al. Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2005;122:107-111 (Pubitemid 41265689)
11. Dunton CJ, Baak JP, Palazzo JP, et al. Use of computerized morphometric analyses of endometrial hyperplasia in the prediction of coexistent cancer. Am J Obstet Gynecol 1996;174:1518-1521 (Pubitemid 26165271)
12. Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group Study. Cancer 2006;106:812-819 (Pubitemid 43238448)
13. Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982;49:2547-2559
14. Janicek MF, Rosenshein NB. Invasive endometrial cancer in uteri resected for atypical endometrial hyperplasia. Gynecol Oncol 1994;52:373-378 (Pubitemid 24125555)
15. Widra EA, Dunton CJ, McHugh M, et al. Endometrial hyperplasia and the risk of carcinoma. Int J Gynecol Cancer 1995;5:233-235
16. Xie X, Lu WG, Ye DF, et al. The value of curettage in diagnosis of endometrial hyperplasia. Gynecol Oncol 2002;84:135-139 (Pubitemid 34056479)
17. Zaino RJ, Kauderer J, Trimble CL, et al. Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group Study. Cancer 2006;106:804-811 (Pubitemid 43238447)
18. Mylonas I, Makovitzky J, Richter DU, et al. Expression of the inhibin-alpha subunit in normal, hyperplastic and malignant endometrial tissue: an immunohistochemical analysis. Gynecol Oncol 2004;93:92-97 (Pubitemid 38429554)
19. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-577 (Pubitemid 32601237)
20. Kreiger N, Marrett LD, Clarke EA, et al. Risk factors for adenomatous endometrial hyperplasia: a case-control study. Am J Epidemiol 1986;123:291-301. (Pubitemid 16158551)
21. Gredmark T, Kvint S, Havel G, et al. Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium. Gynecol Oncol 1999;72:138-142 (Pubitemid 29093765)
22. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995;80:2057-2062
23. Pasquali R, Vicennati V, Bertazzo D, et al. Determinants of sex hormone-binding globulin blood concentration in premenopausal and postmenopausal women with different estrogen status. Virgilio-Menopause-Health Group. Metabolism 1997;46:5-9. (Pubitemid 27052016)
24. Petridou E, Belechri M, Dessypris N, et al. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab 2002;46:147-151 (Pubitemid 34920698)
25. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-1163 (Pubitemid 38368405)
26. Housa D, Housova J, Vernerova Z, et al. Adipocytokines and cancer. Physiol Res 2006;55:233-244
27. Roberts-Thomson SJ. Peroxisome proliferators-activated receptors in tumorigenesis: targets of tumor promotion and treatment. Immunol Cell Biol 2000;78:436-441 (Pubitemid 30655570)
28. Fajas L, Debril MB, Auwerx J. Peroxisome proliferators-activated receptor-gamma: from adipogenesis to carcinogenesis. J Mol Endocrinol 2001;27:1-9. (Pubitemid 32771453)